Is This Cheap Cancer-Drug Company a Top Stock to Buy Now?
Over the past year, TG Therapeutics (NASDAQ: TGTX) has been one of the top-performing cancer treatment stocks, with a stunning return of 190% as of Feb. 18. That's wild considering the industry benchmark iShares NASDAQ Biotechnology ETF (NASDAQ: IBB) returned just 37% over the same period.
As it turns out, TG Therapeutics is still significantly undervalued, even after its 2020 rally. Could larger companies be eyeing TG Therapeutics for its acquisition potential? Let's look at what the company has to offer in its efforts to combat cancer.
Image Source: Getty Images.
Source Fool.com
